Cixutumumab.
The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.
McKian
Kevin P
KP
Mayo Clinic College of Medicine, Division of Medical Oncology, 200 First St. SW Rochester, MN 55905, USA.
Haluska
Paul
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D017526:Receptor, IGF Type 1 / Q000276:immunology*; D015398:Signal Transduction / Q000276:immunology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D017526:Receptor, IGF Type 1